Premenstrual syndromes: Closing the 20th century chapters

Current Opinion in Obstetrics and Gynecology

Volumn 11, Issue 3, 1999, Pages 265-270

  Halbriech, Uriel ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CITALOPRAM; CLOMIPRAMINE; DANAZOL; DEXFENFLURAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GONADORELIN AGONIST; HORMONE; LEUPRORELIN; PAROXETINE; PROTIRELIN; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN;

ARTICLE; COMORBIDITY; DIET SUPPLEMENTATION; DYSPHORIA; EXERCISE; FEMALE; HUMAN; MASTALGIA; MENTAL DISEASE; PALLIATIVE THERAPY; PATHOLOGY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SOCIAL SUPPORT;

FEMALE; GYNECOLOGY; HUMANS; PREMENSTRUAL SYNDROME;

EID: 0032876663     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199906000-00006     Document Type: Article

References (121)

1. Freeman EW. Premenstrual syndrome: Current perspectives on treatment and etiology. Curr Opin Obstet Gynecol 1997; 9:147-153.
2. Freeman EW, Halbreich U. Premenstrual syndromes. Psychopharmacol Bull 1998; 34:291-295.
3. Halbreich U. Menstrually related disorders: What we do know, what we only believe that we know, and what we know that we do not know. Crit Rev Neurobiol 1995; 9:163-175.
4. Halbreich U. Pre-menstrual syndromes. Bailliere's Clin Psych 1996; 2:667-686.
5. Halbreich U. Premenstrual dysphoric disorders: A diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 1997; 95:169-176.
6. Mortola, JF. Premenstrual syndrome - Pathophysiologic considerations. New Engl J Med 1998; 338: 256-257.
7. Parry BL. Psychobiology of premenstrual dysphoric disorder. Semin Reprod Endocrinol 1997; 15:55-68.
8. Korzekwa MI, Steiner M. Premenstrual syndromes. Clin Obstet Gynecol 1997; 40:564-576.
9. Vanselow W. A comprehensive approach to premenstrual complaints. Aust Fam Physician 1998; 27:354-361.
10. Mortola JF. Premenstrual syndrome. Curr Ther Endocrinol Metab 1997; 6:251-256.
11. Redmond G. Mood disorders in the female patient. Int J Fertil 1997; 42:67-72.
12. Steiner M. Premenstrual syndromes. Annu Rev Med 1997; 48:447-455.
13. O'Brien PMS. Clinical concerns with premenstrual syndrome. Cephalalgia 1997; 17 (suppl 20):8-11.
14. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 (suppl 15):19-25.
15. Szewczyk M, Chennault SA. Depression and related disorders. Primary Care 1994; 24:83-101.
16. Yonkers KA. Anxiety symptoms and anxiety disorders: How are they related to premenstrual disorders? J Clin Psychiatry 1997; 58 (suppl 3):62-67.
17. Facchinetti F, Tarabusi M, Nappi G. Premenstrual syndrome and anxiety disorders: A psychobiological link. Psychother Psychosom 1998; 67:57-60.
18. Chau J, Chang AM, Chang A. Relationship between premenstrual tension syndrome and anxiety in Chinese adolescents. J Adolesc Health 1998; 22:247-249.
19. Baca-Garcia E, Gonzalez SA, Diaz-Corralero PG, Garcia IG, de Leon J. Menstrual cycle and profiles of suicidal behaviour. Acta Psychiatr Scand 1998; 97:32-35.
20. Levitte SS. Treatment of premenstrual exacerbation of schizophrenia. Psychosomatics 1997; 38:582-584.
21. Williams KE, Koran LM. Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J Clin Psychiatry 1997; 58:330-334.
22. Keuthen NJ, O'Sullivan RL, Hayday CF, Peets KE, Jenike MA, Baer L. The relationship of menstrual cycle and pregnancy to compulsive hairpulling. Psychother Psychosom 1997; 66:33-37.
23. Dye L, Blundell JE. Menstrual cycle and appetite control: Implications for weight regulation. Hum Reprod 1997; 12:1142-1151.
24. Verri A, Nappi RE, Vallero E, Galli C, Sances G, Martignoni E. Premenstrual dysphoric disorder and eating disorders. Cephalalgia 1997; 17 (suppl 20):25-28.
25. Kornstein SG, Parker AJ. Menstrual migraines: Etiology, treatment, and relationship to premenstrual syndrome. Curr Opin Obstet Gynecol 1997; 9:154-159.
26. Welch KMA. Migraine and ovarian steroid hormones. Cephalalgia 1997; 17 (suppl 20):12-16.
27. Benedetto C, Allais G, Ciochetto D, De Lorenzo C. Pathophysiological aspects of menstrual migraine. Cephelalgia 1997; 17 (suppl 20):32-34.
28. Granella F, Sances G, Messa G, de Marinis M, Manzoni GC. Treatment of menstrual migraine. Cephalalgia 1997; 17 (suppl 20):35-38.
29. Blumer D, Herzog AG, Himmelhoch J, Salgueiro CA, Ling FW. To what extent do premenstrual and interictal dysphoric disorder overlap? Significance for therapy. J Affect Disord 1998; 48:215-225.
30. Lundberg PO. Catamenial epilepsy: A review. Cephalalgia 1997; 17 (suppl 20):42-45.
31. Renton CM, Persinger MA. Elevations of complex partial epileptic-like experiences during increased geomagnetic activity for women reporting 'premenstrual syndrome'. Perceptual & Motor Skills 1998; 86:240-242.
32. Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. Am J Obstet Gynecol 1997; 177:126-132.
33. Tavaf-Motamen H, Ader DN, Browne MW, Shriver CD. Clinical evaluation of mastalgia. Arch Surg 1998; 133:211-213.
34. Goodwin PJ, Miller A, Del Giudice ME, Ritchie K. Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. Am J Obstet Gynecol 1997; 176:998-1005.
35. Ostensen M, Rugelsjoen A, Horven Wigers S. The effect of reproductive events and alterations of sex hormone levels on the symptoms of fibromyalgia. Scand J Rheumatol 1997; 26:355-360.
36. Chandler M, Schuldheisz S, Phillips BA, Muse KN. Premenstrual asthma: The effect of estrogen on symptoms, pulmonary function, and B2-receptor. Pharmacotherapy 1997; 17:224-234.
37. Mirdal GM, Peterson B, Weeke B, Vibits A. Asthma and menstruation: The relationship between psychological and bronchial hyperreactivity. Br J Med Psychol 1998; 71:47-55.
38. Agarwat AK, Shah A. Menstrual-linked asthma. J Asthma 1997; 34:539-545.
39. Stephens C. Young women and perimenstrual eruptions. Clin Dermatol 1997; 15:31-34.
40. Shelley ED, Shelley WB, Talanin NY. The mysterious case of the premenstrual purple chin. Cutis 1997; 60:147-149.
41. Marean M, Fox EE, Cumming CE, Cumming DC. Irritability and sociability in women with symptomatic premenstrual change. Women & Health 1998; 27:65-71.
42. Maskall DD, Lam RW, Misri S, Carter D, Kuan AJ, Yatham LN, Zis AP. Seasonality of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiatry 1997; 154:1436-1441.
43. Bloch MB, Schmidt PJ, Rubinow DR. Premenstrual syndrome: Evidence for symptom stability across cycles. Am J Psychiatry 1997; 154:1741-1746.
44. Halbreich U. Menstrually related disorders - Towards interdisciplinary international diagnostic criteria. Cephalalgia 1997; 17 (suppl 26):1-4.
45. Kendler K, Karkowski L, Corey L, Neale M. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998: 155:1234-1240.
46. Schmidt P, Nieman L, Danaceau M, Adams L, Rubinow D. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209-216.
47. Sundström I, Andersson A, Nyberg S, Ashbrook D, Purdy R, Bäckström T. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67:126-138. This study underscores the different diversified sensitivity of women with PMS.
48. Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma GABA during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153:718-720.
49. Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrionology 1997; 22:25-38.
50. Sundström I, Nyberg S, Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17:370-381.
51. Rapkin A, Morgan M, Goldman L, Brann D, Simone D, Mahesh V. Progesterone metabolite alloprognanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90:709-714. This study confirmed the changes in progesterone metabolites in PMS and demonstrated the increased awareness of the interactions between steroids and neurotransmitters.
52. Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnanolone, pregnanolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5 alpha-pregnan-20-one. J Clin Endocricol Metab 1996; 81:1076-1082.
53. Biciková M, Dibbelt L, Hill M, Hampl R, Stárka L. Allopregnanolone in women with premenstrual syndrome. Horm Metab 1998; 30:227-230.
54. Berga S. Understanding premenstrual syndrome. Lancet 1998; 351: 465-466.
55. Fry J, Honour J. Understanding premenstrual syndrome. Lancet 1998; 351:1511-1512.
56. Britton KT, Koob GF. Premenstrual steroids? Nature 1998; 392:860-870. An elegant brief review of the role of steroids in PMS.
57. Halbreich U, Endicott J, Goldstein S, Nee J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 1985; 74:576-586.
58. Halbreich U. Hormones and depression. New York: Raven Press; 1987.
59. A receptor α4 subunit in association with increased anxiety. J Neurosci 1998; 18: 5275-5284. An animal model for a subgroup of PMS?
60. A receptor α4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998; 392:926-930. Application of the animal model to demonstrate the bi-directional interaction between the GABA system and steroids.
61. Woods NF, Lentz MJ, Mitchell ES, Shaver J, Heitkemper M. Luteal phase ovarian steroids, stress arousal, premenses perceived stress, and premenstrual symptoms. Research in Nursing & Health 1998; 21:129-142.
62. Seippel L, Bäckström T. Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome. J Clin Endocrinol Metab 1998; 83: 1988-1992.
63. Bloch M, Schmidt PJ, Su T, Tobin M, Rubinow D. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiatry 1998; 43:897-903.
64. Dougherty DM, Bjork JM, Moeller FG, Swann AC. The influence of menstrual-cycle phase on the relationship between testosterone and aggression. Physiol Behav 1997; 62:431-435.
65. Parry BL, LeVeau B, Mostofi N, Naham HC, Loving R, Clopton P, Gillin JC. Temperature circadian rhythms during the menstrual cycle and sleep deprivation in premenstrual dysphoric disorder and normal comparison subjects. J Biol Rhythms 1997; 12:34-46.
66. Nakayama K, Nakagawa T, Hiyama T, Katsu H, Wakutsu N, Koga M, Usijima S. Circadian changes in body temperature during the menstrual cycle of healthy adult females and patients suffering from premenstrual syndrome. Int J Clin Pharm Res 1997; XVII:155-164.
67. Parry BL, Berga SL, Mostofi N, Klauber MR, Resnick A. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms 1997; 12:47-64.
68. Parry BL, Udell C, Elliott JA, Berga SL, Klauber MR, Mostofi N, et al. Blunted phase-shift responses to morning bright light in premenstrual dysphoric disorder. J Biol Rhythms 1997; 12:443-456.
69. Chuong CJ, Kim SR, Taskin O, Karacan I. Sleep pattern changes in menstrual cycles of women with premenstrual syndrome: A preliminary study. Am J Obstet Gynecol 1997; 177:554-558.
70. Einon D. The influence of ambient light and menstrual status on the moods of a nonclinical population of young women. Psychosom Med 1997; 59;616-619.
71. Desmond NL, Levy WB. Ovarian steroidal control of connectivity in the female hippocampus; an overview of recent experimental findings and speculations on its functional consequences. Hippocampus 1997; 7:239-245.
72. Muneyyirci-Delale O, Nacharaju VL, Altura BM, Altura BT. Sex steroid hormones modulate serum ionized magnesium and calcium level throughout the menstrual cycle in women. Fertil Steril 1998; 69:958-962.
73. Sowers M, Randolph JF Jr, Crutchfield M, Jannausch ML, Shapiro B, Zhang B, La Pietra M. Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass. J Bone Miner Res 1998; 13:1191-1202.
74. Gorai Itsuo, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, et al. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 1998; 83:326-332.
75. Price TM, O'Brien SN, Welter BH, George R, Anandjiwala J, Kilgore M. Estrogen regulation of adipose tissue lipoprotein lipase - Possible mechanism of body fat distribution. Am J Obstet Gynecol 1998; 178:101-107.
76. Kimura T, Hayakawa F, Yamamoto G, Yoshitake K, Ando T. Variation of the total amount of fluoride in blood of young women during the menstrual cycle. Int J Vit Nutr Res 1998; 68:63-67.
77. Ferrer J, Mtnez-Guisasola J, Diaz F, Alonso F, Guerrero M, Marin B. Plasma levels of β-endorphin during the menstrual cycle. Gynecol Endocrinol 1997; 11:75-82.
78. Stern K, McClintock MK. Regulation of ovulation by human pheromones. Nature 1998; 392:177-179.
79. De Crèe C, Van Kranenburg G, Geurten P, Fujimori Yoshiyuki, Keizer HA. 4-hydroxycatecholestrogen metabolism responses to exercise and training: Possible implications for menstrual cycle irregularities and breast cancer. Fertil Steril 1997; 67:505-516.
80. De Crèe C. Sex steroid metabolism and menstrual irregularities in the exercising female. Sports Med 1998; 25:369-406.
81. Stewart DR, Erikson MS, Erikson ME, Nakajima ST, Overstreet JW, Lasley BL, et al. The role of relaxin in glycodelin secretion. J Clin Endocrinol Metab 1997; 82:839-846.
82. Van Goozen SHM, Wiegant VM, Endert E, Helmond FA, Van de Poll NE. Psychoendocrinological assessment of the menstrual cycle: The relationship between hormones, sexuality, and mood. Arch Sexual Behav 1997; 26:359-382.
83. Mustonen MVJ, Isomaa W, Vaskivuo T, Tapanainen J, Poutanen MH, Stenbäck F, et al. Human 17β-hydroxysteriod dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle. J Clin Endocrinol Metab 1998; 83:1319-1324.
84. Söderqviat G, Poutanen M, Wickman M, von Schoultz B, Skoog L, Vihko R. 17β-hydroxysteriod dehydrogenase 1 in normal breast tissue during the menstrual cycle and hormonal contraception. J Clin Endocrinol Metab 1998; 83:1190-1193.
85. Moutsatsou P, Sekeris CE. Estrogen and progesterone receptors in the endometrium. Ann NY Acad Sci 1998; 816:99-115.
86. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes. Schizophrenia Bull 1996; 22:447-454.
87. Levitan RD, Kaplan AS, Brown G, Vaccarino FJ, Kennedy SH, Levitt AJ, Joffe RJ. Hormonal and subjective responses to intravenous m-chlorophenylpiperazine in women with seasonal affective disorder. Arch Gen Psychiatry 1998; 55:244-249.
88. Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. In: Mood Disorders, Systemic Medication Management. Rush AJ (editor). Basel: Karger; 1997. pp. 146-166.
89. Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry 1997; 58 (suppl 14): 4-10.
90. Su T-P, Schmidt PJ, Danaceau MA, Tobin MB, Rosenstein DL, Murphy DL, Rubinow DR. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16:346-356.
91. Özeren S, Çoraķi, Izzet Y. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obset Gynecol Reprod Biol 1997; 73:167-170.
92. Steiner M, Lamong J, Steinberg S. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet Gynecol 1997; 90:590-595.
93. Yonkers K, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial. JAMA 1997; 278:983-988. A large scale clinical trial confirming the efficacy of SSRIs for the treatment of PMS (although with only 60% success rate).
94. Gunasekara NS, Noble S, Bernfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55:85-120.
95. Sunderström I, Bäckström T. Citalopram increases pregnenolone sensitivity in patients with premenstrual syndrome: An open trial. Psychoneuroendocrinology 1998; 23:73-88. The authors demonstrate that SSRIs affect not only 5- hydrexytryptamine but also its interactions with steroids.
96. Pearlstein TB, Stone AG, Lund SA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmecol 1997; 17:261-266.
97. Cohen L. Sertraline for premenstrual dysphoric disorder [letter]. JAMA 1998; 279:357-358.
98. Yonkers KA, Halbreich U, Brown C, Pearlstein T, Freeman E, Endicott J, et al. In reply. JAMA 1998; 279;358.
99. Fernandes O, Pin Por C, Evans MF. Is sertraline an effective therapy for premenstrual dysphoric disorder? Canadian Fam Physician 1998; 44:765-767.
100. Halbreich U, Smoller J. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58:399-402. This paper demonstrates that, in patients with PMS, intermittent treatment with SSRI is as effective as a continuous treatment.
101. Steiner M, Korzekawa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacology Bull 1997; 33:771-774. The authors confirmed the results in [100]: this therefore points to a generalization, although with a long-term compound.
102. Comparison of seretonergic and noredrenergic antidepressant medications in the treatment of premenstural syndrome. CINP Congress 1998, Glasgow, Scotland.
103. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59: 76-80.
104. Jermain DM, Preece CK, Sykes RL. Luteal phase sertraline treatment for premenstrual dysphoric disorder: Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med (in press).
105. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full or half cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19:3-8.
106. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study. Psychopharmacol Bull 1997; 33:303-309.
107. Kontostolis E, Stefanidis K, Navrozoglou I, Lolis D. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia. Gynecol Endocrinol 1997; 11:393-397.
108. Rea N, Bove F, Gentile A, Parmeggiani U. Prolactin response to thyrotropin-releasing hormone as a guideline for cyclical mastalgia treatment. Minerva Medica 1997; 288:479-487.
109. Facchinetti F, Nappi RE, Sances MG. Effects of a yeast-based dietary supplementation on premenstrual syndrome. Gynecol Obstet Invest 1997; 43:120-124.
110. Christensen, L. The effect of carbohydrates on affect. Nutrition 1997; 13:503-514.
111. Scully D, Kremer J, Meade MM, Graham R, Dudgeon K. Physical exercise and psychological well being: A critical review. Br J Sports Med 1998; 32:111-120.
112. Morse GG. Effect of positive reframing and social support on perception of perimenstrual changes among women with premenstrual syndrome. Health Care Women Int 1997; 18:175-193.
113. Fontana AM, Badawy S. Perceptual and coping processes across the menstrual cycle: An investigation in a premenstrual syndrome clinic and a community sample. Behav Med 1997; 22:152-159.
114. Henderson BJ, Whissell C. Changes in women's emotions as a function of emotion valence, self-determined category of premenstrual distress, and day in the menstrual cycle. Psychological Reports 1997; 80:1272-1274.
115. Singh BB, Berman BM, Simpson RL, Annechild A. Incidence of premenstrual syndrome and remedy usage: A national probability sample study. Altern Ther Health Med 1998; 4:375-379.
116. Campbell EM, Peterkin D, O'Grady K, Sanson-Fisher R. Premenstrual symptoms in general practice patients: Prevalence and treatment. J Reprod Med 1997; 42:637-646.
117. Cleckner-Smith CS, Doughty AS, Grossman JA. Premenstrual symptoms. Prevalence and severity in an adolescent sample. J Adolesc Health 1998; 22:5403-5408.
118. Woods NF, Lentz M, Mitchell ES, Heitkemper M, Shaver J. PMS after 40: persistence of a stress-related symptom pattern. Res Nurs Health 1997; 20:4329-4340.
119. Larsson C, Hallman J. Is severity of premenstrual symptoms related to illness in the climacteric? J Psychosom Obstet Gynecol 1997; 18:234-243.
120. McMaster J, Cormie K, Pitts M. Menstrual and premenstrual experiences of women in a developing country. Health Care Women Int 1997; 18:533-541.
121. Young E, Korezun A. Psychonueroendocrinology of depression. Hypothalamic-pituitary-gonadal axis. Psychiatr Clin North Am 1998; 21:309-323.